ABSTRACT
Fusidane-type antibiotics, represented by helvolic acid, fusidic acid and cephalosporin P
ABSTRACT
Objective To observe the expression levels of serum osteopontin (OPN),adenosine kinase 1 (TK1) and secretory protein Dikkopf 1 (DKK1) in patients with lung cancer and their clinical significances.Methods Lung cancer patients treated in the First Affiliated Hospital of Xi'an Medical University from February 2017 to April 2018 were selected as the lung cancer group (60 cases),and 60 healthy adults who received physical examination in the same period were selected as the control group.The differences of serum OPN,TK1 and DKK1 levels between the lung cancer group and the control group and lung cancer patients with different characteristics were compared.Measurement data were compared by using t test.Results The levels of serum OPN,TK1 and DKK1 in lung cancer patients were (38.56±3.18) μg/L,(4.69±1.03) pmol/L and (3.76±0.89) ng/ml,respectively,which were higher than those in the control group [(15.98±2.06) μg/L,(1.01±0.22)pmol/L,(1.21±0.24) ng/ml;t =-46.162,-27.064,-21.428,all P ＜ 0.01].The levels of serum OPN,TK1 and DKK1 in lung cancer patients of different ages and gender had no statistical differences (all P ＞ 0.05).The levels of serum OPN,TK 1 and DKK1 in stage Ⅲ-Ⅳ lung cancer patients were (57.18 ±3.12) μg/L,(6.26±1.28) pmol/L and (4.98±1.03) ng/ml,respectively,which were higher than those in stage Ⅰ-Ⅱ lung cancer patients [(30.35±2.96) μg/L,(3.49±0.67) pmol/L,(3.01±0.96) ng/ml;t =-34.156,-10.690,-7.665,all P ＜ 0.01].The levels of serum OPN,TK 1 and DKK1 in non-small cell lung cancer (NSCLC) patients were (55.13±5.02) μg/L,(5.96±1.11) pmol/L and (5.02±1.32) ng/ml,respectively,which were higher than those in small cell lung cancer (SCLC) patients [(29.68±3.16) μg/L,(3.13±0.98) pmol/L,(2.86±0.56) ng/ml;t =-22.353,-10.213,-7.688,all P ＜ 0.01].Conclusion The levels of serum OPN,TK1 and DKK1 in patients with lung cancer are higher,which are related to the type and stage of lung cancer.
ABSTRACT
Objective@#To study the influence of allopurinol and febuxostat on IL-1β and NALP3 levels and liver and kidney function in gout patients with hyperuricemia.@*Methods@#A total of 108 patients with stable gout accompanied by hyperuricemia were selected and randomly divided into control group and observation group according to the digital table, with 54 cases in each group.The control group was given allopurinol 100mg/time, orally, 3 times/d.The observation group was given febuxostat 40mg/time, orally, 1 time/d.The two groups were treated 4 weeks for 1 course, continuous treatment for 6 courses.The contents of serum IL-1β and NALP3, and renal function[creatinine(Scr), urea nitrogen(BUN), glomerular filtration rate(GFR) and uric acid(UA)], liver function[alanine aminotransferase(ALT) and aspartate aminotransferase(AST)]of the two groups were detected, and the adverse reaction of the two groups were observed.@*Results@#After treatment, the contents of serum IL-1β and NALP3 of the observation group decreased gradually, which were lower than those of the control group(t=1.910, 2.196, 4.954, 1.732, 5.944, 7.935, all P<0.05). After treatment, the blood UA of the two groups decreased significantly, the blood UA of the observation group was lower than the control group(t=9.772, P<0.05). The other kidney function indicators had no statistically significant differences between the two groups (t=0.082, 0.923, 1.395, all P>0.05). The liver function indicators of the two groups had no statistically significant differences(t=0.860, 0.563, all P>0.05). The incidence rate of adverse reactions in the observation group was 5.77%, which was lower than 20.75% in the control group(χ2=5.101, P=0.024).@*Conclusion@#Febuxostat in the treatment of gout with hyperuricemia can effectively reduce the level of serum UA, and inhibit the expression of inflammatory factors such as IL-1β and NALP3, with high safety, which is worthy of clinical promotion.